Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jana Bergelin"'
Autor:
Jana Bergelin, J Beck, Volker Ellenrieder, Boris G. Naraev, E Schütz, S Payr, Jochen Gaedcke, Madappa N. Kundranda, Alexander König, Kirsten Bornemann-Kolatzki, Tomislav Dragovich
Publikováno v:
Zeitschrift für Gastroenterologie.
Autor:
S Payr, Boris G. Naraev, E Schütz, Azadeh Azizian, Jana Bergelin, Alexander König, Tomislav Dragovich, J Beck, Volker Ellenrieder, Jochen Gaedcke, Marius Brunner, Ute König, Madappa N. Kundranda
Publikováno v:
Annals of Oncology. 30:v274-v275
Background Genomic instability as characteristic for malignant transformation can be identified by quantitative sequencing. Cell-free tumor DNA (cfDNA) is a minimal invasive biomarker that can be used for tumor and therapeutic monitoring. This study
Autor:
Jana Bergelin, Ekkehard Schütz, Tomislav Dragovich, Howard B. Urnovitz, Patricia Lucente, Madappa N. Kundranda, Boris G. Naraev, Marie Conn, Julia Beck, John Chang
Publikováno v:
Journal of Clinical Oncology. 37:261-261
261 Background: Cell-free tumor DNA (cfDNA) has potential to provide minimally invasive patient specific biomarkers to monitor tumor burden. Tumor-specific copy number instability (CNI) are used to quantify tumor-derived cfDNA in the plasma. We prosp
Autor:
Jessica Coats, Julia Beck, Kirsten Bornemann-Kolatzki, Jana Bergelin, Tomislav Dragovich, Glen J. Weiss, Ekkehard Schütz, Alexander Koenig, Volker Ellenrieder, William M. Mitchell, Howard B. Urnovitz, Madappa N. Kundranda, Jordan Waypa
Publikováno v:
Journal of Clinical Oncology. 35:e14524-e14524
e14524 Background: Humoral tumor markers are used clinically for real-time assessment of therapeutic efficacy. In pancreatic ductal adenocarcinoma (PDAC) the predominant marker is CA19-9, which is not expressed by 10 to 30% of patients depending on r